Cognitive Effects of Immunomodulatory Drugs in MS
Information source: University of Kansas
Information obtained from ClinicalTrials.gov on June 20, 2008
Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Multiple Sclerosis
Status: Active, not recruiting
Sponsored by: University of Kansas
Official(s) and/or principal investigator(s):
Sharon G Lynch, MD, Principal Investigator, Affiliation: University of Kansas
Douglas R Denney, PhD, Principal Investigator, Affiliation: University of Kansas
The purpose of this study is to examine and compare changes in the specific thinking skills
of patients with RRMS who are receiving treatment with one of three immunomodulatory
medications (Avonex, Copaxone, or Rebif).
Official title: Comparison of the Cognitive Effects of Three Immunomodulatory Drugs in Relapsing-Remitting Multiple Sclerosis: A Longitudinal Study
Study design: Cohort, Prospective
In addition this study will compare the patients' personal view of how they are doing, any
changes in physical disability, and the frequency and severity of relapses over the three
Minimum age: 18 Years.
Maximum age: 60 Years.
- Diagnosis of RRMS for at least one year,
- Currently on one of three immunomodulatory drugs (Avonex, Copaxone, or Rebif),
- Visual Acuity is 20/50 or better,
- patient has four color vision,
- Must have at least a high school education
- History of head injury, drug/alcohol abuse, and/or psychiatric problems, -current
diagnosis of a severe or lifethreatening disease other than MS,
- currently taking immunosuppressant medication,
- resides greater than 200 miles from the study site
Locations and Contacts
University of Kansas Medical Center, Kansas City, Kansas 66160, United States
Starting date: September 2005
Ending date: January 2010
Last updated: June 12, 2008